RE:RE:Todays NewsCompletely agree. Unless KNR reports a large sale to government or a commercial entity, I can't see there being much in the way of sales until Q2 and beyond. It's possible we'll see a big order, which is why I stay invested rather than trading in and out of the stock, but I'm not going to count on it either. More likely we're going to see incremental sales growth, which should continue to ramp up over the coming quarters as the biocloud continues to get proven out.
Bottom line: the company is worth more than its current share price, but it remains to be seen how fast and far it will run.
canyousayiii wrote: We are unlikely to see much in Q4 in terms of sales, and probably not much in Q1. There are plenty of clues pointing to that. The first interesting quarter will be Q2 but that reporting is eons from now and in the meantime should see some news about sales.